Series A · Agritech & Foodtech · Helsinki, Finland · Founded 2022 · 50–60 employees
Onego Bio produces Bioalbumen, an animal-free egg white protein using precision fermentation technology with Trichoderma reesei fungus. The Finnish biotech company has raised $65.2M total funding including a $40M Series A in 2024 and secured FDA GRAS status for commercialization. Their bioidentical egg protein offers 90% lower environmental impact while maintaining the same functionality, nutrition and taste as traditional egg whites. The company is targeting the $300 billion global egg market with plans to launch first in the US market in 2024.
No open roles listed right now.